Calidi Biotherapeutics, Inc.
$0.25
▼
-2.72%
2026-04-21 06:04:00
www.calidibio.com
ASE: CLDI
Explore Calidi Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3 M
Current Price
$0.25
52W High / Low
$19.2 / $0.21
Stock P/E
—
Book Value
$0.51
Dividend Yield
—
ROCE
-410.2%
ROE
-7.01%
Face Value
—
EPS
$-5.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
29
Beta
1.42
Debt / Equity
68.21
Current Ratio
1.59
Quick Ratio
1.59
Forward P/E
-0.29
Price / Sales
—
Enterprise Value
$-0.2 M
EV / EBITDA
0.01
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Acumen Pharmaceuticals, Inc. | $2.84 | — | $203.64 M | — | -133.4% | -96.2% | $3.6 / $0.85 | $1.16 |
| 2. | Intensity Therapeutics, Inc. | $5.21 | — | $13.46 M | — | -100.14% | -1.57% | $50 / $4.63 | $4.7 |
| 3. | Fortrea Holdings Inc. | $10.44 | — | $976.14 M | — | -1.7% | -1.02% | $18.67 / $3.97 | $6.05 |
| 4. | Sionna Therapeutics, Inc. | $42.64 | — | $1.96 B | — | -28.32% | -31.79% | $46.46 / $9.24 | $6.86 |
| 5. | Oruka Therapeutics, Inc. | $68.87 | — | $3.48 B | — | -25.79% | -24.69% | $70.5 / $8.36 | $9.63 |
| 6. | Heron Therapeutics, Inc. | $1.05 | — | $187.09 M | — | -1.59% | 209.08% | $2.61 / $0.74 | $0.07 |
| 7. | OS Therapies Incorporated | $1.38 | — | $58.43 M | — | 582.87% | 614.26% | $2.57 / $1.15 | $-0.16 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.47 M | -5.05 M | -5.66 M | -5.01 M | -4.03 M | — |
| Net Profit | -4.06 M | -5.15 M | -5.71 M | -4.99 M | -4.1 M | — |
| EPS in Rs | -0.37 | -0.47 | -0.52 | -0.46 | -0.38 | -7.75 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.04 M |
| Operating Profit | -20.19 M | -21.59 M | -26.11 M | -23.13 M |
| Net Profit | -19.91 M | -22.14 M | -29.22 M | -25.43 M |
| EPS in Rs | -1.83 | -2.03 | -2.68 | -2.33 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.86 M | 14.18 M | 10.02 M | 2.6 M |
| Total Liabilities | 5.1 M | 12.21 M | 18.25 M | 53.04 M |
| Equity | 3.76 M | 1.53 M | -8.23 M | -50.44 M |
| Current Assets | 6.26 M | 10.23 M | 4.3 M | 0.79 M |
| Current Liabilities | 3.94 M | 9.5 M | 10.23 M | 42.99 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -21.29 M | -19.69 M | -26.98 M | -13.21 M |
| Investing CF | -0.17 M | -0.02 M | -0.48 M | -0.49 M |
| Financing CF | 17.46 M | 27.36 M | 29.04 M | 12.09 M |
| Free CF | -21.41 M | -19.71 M | -27.57 M | -13.64 M |
| Capex | -0.12 M | -0.02 M | -0.58 M | -0.43 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 24.21% | -14.9% | — | — |
| Profit Margin % | — | — | -56504.44% | — |
| Operating Margin % | — | — | -51395.56% | — |
| Gross Margin % | — | — | 68.89% | — |
| EBITDA Margin % | — | — | -55566.67% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-08-05 | 1:0.0833333 |
| 2024-07-15 | 1:0.1 |